Epidemiological-molecular evidence of metabolic reprogramming on proliferation, autophagy and cell signaling in pancreas cancer

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 281-288

  Søreide, Kjetil ^a,b   Sund, Malin ^c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Autophagy; Cancer metabolism; Glycolysis; KRAS mutation; Pancreas cancer

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUTAMINE; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN P53; HMGB1 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR ANTIGEN;

AUTOPHAGY; CALORIC INTAKE; CANCER METABOLISM; CANCER RISK; CARCINOGENESIS; CELL COMMUNICATION; CELL PROLIFERATION; CELL SIGNALING; DIABETES MELLITUS; EPIDEMIOLOGY; GENETIC VARIABILITY; GENOME; HUMAN; HYPOXIA; INFLAMMATION; KRAS GENE; METABOLIC STRESS; METABOLISM; METABOLOMICS; MOLECULAR GENETICS; NONHUMAN; NUTRIENT; OBESITY; ONCOGENE; PANCREAS CANCER; RISK FACTOR; SHORT SURVEY; ANIMAL; BIOSYNTHESIS; CARCINOMA, PANCREATIC DUCTAL; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; GLYCOLYSIS; MOUSE; NUCLEAR REPROGRAMMING; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; AUTOPHAGY; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; CELLULAR REPROGRAMMING; DIABETES COMPLICATIONS; ENERGY INTAKE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; OBESITY; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920143143     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.028     Document Type: Review

References (91)

1. Søreide K., Aagnes B., Møller B., Westgaard A., Bray F. Epidemiology of pancreatic cancer in Norway: trends in incidence, basis of diagnosis and survival 1965-2007. Scand. J. Gastroenterol. 2010, 45:82-92.
2. Wolfgang C.L., Herman J.M., Laheru D.A., et al. Recent progress in pancreatic cancer. CA Cancer J. Clin. 2013, 63:318-348.
3. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
4. Murphy S.J., Hart S.N., Lima J.F., et al. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology 2013, 145(1098-109):e1.
5. Koorstra J.B., Feldmann G., Habbe N., Maitra A. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbeck Arch. Surg. 2008, 393:561-570.
6. Iacobuzio-Donahue C.A., Velculescu V.E., Wolfgang C.L., Hruban R.H. Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin. Cancer Res. 2012, 18:4257-4265.
7. Biankin A.V., Waddell N., Kassahn K.S., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405.
8. Kern S.E., Shi C., Hruban R.H. The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J. Pathol. 2011, 223:295-306.
9. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl. J. Med. 2013, 369:1691-1703.
10. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
11. Hidalgo M. New insights into pancreatic cancer biology. Ann. Oncol. 2012, 23(Suppl 10). pp. x135-8.
12. Semenza G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 2013, 123:3664-3671.
13. Regel I., Kong B., Raulefs S., et al. Energy metabolism and proliferation in pancreatic carcinogenesis. Langenbeck Arch. Surg. 2012, 397:507-512.
14. Vasseur S., Tomasini R., Tournaire R., Iovanna J.L. Hypoxia induced tumor metabolic switch contributes to pancreatic cancer aggressiveness. Cancers (Basel) 2010, 2:2138-2152.
15. Le A., Rajeshkumar N.V., Maitra A., Dang C.V. Conceptual framework for cutting the pancreatic cancer fuel supply. Clin. Cancer Res. 2012, 18:4285-4290.
16. Vander Heiden M.G. Exploiting tumor metabolism: challenges for clinical translation. J. Clin. Invest. 2013, 123:3648-3651.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Jiao L., Li D. Epidemiology and prospects for prevention of pancreatic cancer. Pancreatic Cancer 2010, 3-26. Springer. J.P. Neoptolemos, R. Urrutia, J.L. Abbruzzese, M.W. Büchler (Eds.).
19. Arslan A.A., Helzlsouer K.J., Kooperberg C., et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch. Int. Med. 2010, 170:791-802.
20. Rohrmann S., Linseisen J., Nothlings U., et al. Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 2013, 132:617-624.
21. Michaud D.S., Vrieling A., Jiao L., et al. Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Cancer Causes Control 2010, 21:1213-1225.
22. Obon-Santacana M., Slimani N., Lujan-Barroso L., et al. Dietary intake of acrylamide and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Ann. Oncol. 2013, 24:2645-2651.
23. Bhoo-Pathy N., Uiterwaal C.S., Dik V.K., et al. Intake of coffee, decaffeinated coffee, or tea does not affect risk for pancreatic cancer: results from the European Prospective Investigation into Nutrition and Cancer Study. Clin. Gastroenterol. Hepatol. 2013, 11:1486-1492.
24. Chuang S.C., Stolzenberg-Solomon R., Ueland P.M., et al. A U-shaped relationship between plasma folate and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Eur. J. Cancer 2011, 47:1808-1816.
25. Leenders M., Bhattacharjee S., Vineis P., et al. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Cancer Causes Control 2013, 24:595-602.
26. Grote V.A., Rohrmann S., Nieters A., et al. Diabetes mellitus, glycated haemoglobin and C-peptide levels in relation to pancreatic cancer risk: a study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Diabetologia 2011, 54:3037-3046.
27. Wolpin B.M., Bao Y., Qian Z.R., et al. Hyperglycemia, insulin resistance, impaired pancreatic beta-cell function, and risk of pancreatic cancer. J. Nat. Can. Inst. 2013, 105:1027-1035.
28. Elena J.W., Steplowski E., Yu K., et al. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 2013, 24:13-25.
29. Tang H., Wei P., Duell E.J., et al. Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: a GWAS data analysis. Cancer Epidemiol. Biomarkers Prevent 2014, 23(1):98-106.
30. Li D., Duell E.J., Yu K., et al. Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis 2012, 33:1384-1390.
31. Grote V.A., Rohrmann S., Dossus L., et al. The association of circulating adiponectin levels with pancreatic cancer risk: a study within the prospective EPIC cohort. Int. J. Cancer 2012, 130:2428-2437.
32. Grote V.A., Kaaks R., Nieters A., et al. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br. J. Cancer 2012, 106:1866-1874.
33. Kang R., Tang D., Lotze M.T., Zeh H.J. AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 2012, 8:989-991.
34. Vernon P.J., Zeh Iii H.J., Lotze M.T. The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products. Oncoimmunology 2013, 2:e24184.
35. Grote V.A., Nieters A., Kaaks R., et al. The associations of advanced glycation end products and its soluble receptor with pancreatic cancer risk: a case-control study within the prospective EPIC Cohort. Cancer Epidemiol. Biomarkers Prevent 2012, 21:619-628.
36. Hruban R.H., Adsay N.V., Albores-Saavedra J., et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. 2001, 25:579-586.
37. Macgregor-Das A.M., Iacobuzio-Donahue C.A. Molecular pathways in pancreatic carcinogenesis. J. Surg. Oncol. 2013, 107:8-14.
38. Neesse A., Hahnenkamp A., Griesmann H., et al. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut 2013, 62:1034-1043.
39. Criscimanna A., Duan L.J., Rhodes J.A., et al. PanIN-specific regulation of Wnt signaling by HIF2alpha during early pancreatic tumorigenesis. Cancer Res. 2013, 73:4781-4790.
40. Yu J., Li A., Hong S.M., Hruban R.H., Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin. Cancer Res. 2012, 18:981-992.
41. Remmers N., Bailey J.M., Mohr A.M., Hollingsworth M.A. Molecular pathology of early pancreatic cancer. Cancer Biomarkers 2010, 9:421-440.
42. Mazur P.K., Einwachter H., Lee M., et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA 2010, 107:13438-13443.
43. Sato N., Fukushima N., Hruban R.H., Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod. Pathol. 2008, 21:238-244.
44. Iacobuzio-Donahue C.A. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut 2012, 61:1085-1094.
45. Yachida S., Jones S., Bozic I., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
46. Collisson E.A., Sadanandam A., Olson P., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 2011, 17:500-503.
47. Urayama S., Zou W., Brooks K., Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid. Commun. Mass Spectrom. 2010, 24:613-620.
48. Leichtle A.B., Ceglarek U., Weinert P., et al. Pancreatic carcinoma, pancreatitis, and healthy controls: metabolite models in a three-class diagnostic dilemma. Metabolomics 2013, 9:677-687.
49. Kobayashi T., Nishiumi S., Ikeda A., et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol. Biomarkers Prevent 2013, 22:571-579.
50. Vareed S.K., Bhat V.B., Thompson C., et al. Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma. PloS one 2011, 6:e17177.
51. Zhang G., He P., Tan H., et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin. Cancer Res. 2013, 19:4983-4993.
52. Davis V.W., Schiller D.E., Eurich D., Bathe O.F., Sawyer M.B. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann. Surg. Oncol. 2013, 20(Suppl 3). pp. S415-23.
53. Napoli C., Sperandio N., Lawlor R.T., Scarpa A., Molinari H., Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J. Proteom. Res. 2012, 11:1274-1283.
54. Al Saati T., Clerc P., Hanoun N., et al. Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas. Am J. Pathol. 2013, 182:1996-2004.
55. Dawson D.W., Hertzer K., Moro A., et al. High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev. Res. 2013, 6:1064-1073.
56. Ying H., Kimmelman A.C., Lyssiotis C.A., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
57. Lanza-Jacoby S., Yan G., Radice G., LePhong C., Baliff J., Hess R. Calorie restriction delays the progression of lesions to pancreatic cancer in the LSL-KrasG12D; Pdx-1/Cre mouse model of pancreatic cancer. Exp. Biol. Med. (Maywood, NJ) 2013, 238:787-797.
58. Kong B., Qia C., Erkan M., Kleeff J., Michalski C.W. Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels. Frontiers Physiol. 2013, 4:246.
59. Philip B., Roland C.L., Daniluk J., et al. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice. Gastroenterology 2013, 145:1449-1458.
60. Shields M.A., Ebine K., Sahai V., et al. Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol. Cancer Res. 2013, 11:1078-1087.
61. Son J., Lyssiotis C.A., Ying H., et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 2013, 496:101-105.
62. Tang H., Wei P., Duell E.J., et al. Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: a GWAS data analysis. Cancer Epidemiol. Biomarkers Prevent. 2014, 23:98-106.
63. Jansen R.J., Robinson D.P., Stolzenberg-Solomon R.Z., et al. Polymorphisms in metabolism/antioxidant genes may mediate the effect of dietary intake on pancreatic cancer risk. Pancreas 2013, 42:1043-1053.
64. Dong X., Tang H., Hess K.R., Abbruzzese J.L., Li D. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer 2011, 117:480-491.
65. Chaika N.V., Yu F., Purohit V., et al. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PloS one 2012, 7:e32996.
66. Wang J., Guo Y., Chu H., Guan Y., Bi J., Wang B. Multiple functions of the rna-binding protein HuR in cancer progression, treatment responses and prognosis. Int. J. Mol. Sci. 2013, 14:10015-10041.
67. Burkhart R.A., Pineda D.M., Chand S.N., et al. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biology 2013, 10:1312-1323.
68. Doherty J.R., Cleveland J.L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 2013, 123:3685-3692.
69. Al-Ahmadi W., Al-Ghamdi M., Al-Souhibani N., Khabar K.S. MiR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J. Pathol. 2013, 230:28-38.
70. Cheng Y.C., Liou J.P., Kuo C.C., et al. MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1alpha mRNA through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR. Mol. Cancer Ther. 2013, 12:1202-1212.
71. Chu P.C., Chuang H.C., Kulp S.K., Chen C.S. The mRNA-stabilizing factor HuR protein is targeted by beta-TrCP protein for degradation in response to glycolysis inhibition. J. Biol. Chem. 2012, 287:43639-43650.
72. von Roretz C., Lian X.J., Macri A.M., et al. Apoptotic-induced cleavage shifts HuR from being a promoter of survival to an activator of caspase-mediated apoptosis. Cell Death Differen. 2013, 20:154-168.
73. Tang D., Loze M.T., Zeh H.J., Kang R. The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy 2010, 6:1181-1183.
74. Kang R., Tang D., Schapiro N.E., et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 2014, 33:567-577.
75. Chung H.W., Lim J.B., Jang S., Lee K.J., Park K.H., Song S.Y. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci. 2012, 103:1714-1721.
76. Wittwer C., Boeck S., Heinemann V., et al. Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients. Int. J. Clin. Pharmacol. Ther. 2013, 51:67-69.
77. Macintosh R.L., Ryan K.M. Autophagy in tumour cell death. Sem. Cancer Biol. 2013, 23:344-351.
78. Gukovsky I., Li N., Todoric J., Gukovskaya A., Karin M. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology 2013, 144(1199-209):e4.
79. Fiorini C., Menegazzi M., Padroni C., et al. Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis 2013, 18:337-346.
80. Hamidi T., Cano C.E., Grasso D., et al. NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells. Autophagy 2013, 9:95-97.
81. Yang S., Kimmelman A.C. A critical role for autophagy in pancreatic cancer. Autophagy 2011, 7:912-913.
82. Fujii S., Mitsunaga S., Yamazaki M., et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008, 99:1813-1819.
83. Yang S., Wang X., Contino G., et al. Pancreatic cancers require autophagy for tumor growth. Gene Dev. 2011, 25:717-729.
84. Rausch V., Liu L., Apel A., et al. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J. Pathol. 2012, 227:325-335.
85. Rosenfeldt M.T., O'Prey J., Morton J.P., et al. P53 status determines the role of autophagy in pancreatic tumour development. Nature 2013, 504:296-300.
86. Kang R., Tang D. Autophagy in pancreatic cancer pathogenesis and treatment. Am. J. Cancer Res. 2012, 2:383-396.
87. Kang R., Tang D., Schapiro N.E., et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differen. 2010, 17:666-676.
88. Hensley C.T., Wasti A.T., DeBerardinis R.J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 2013, 123:3678-3684.
89. Zhou W., Capello M., Fredolini C., et al. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. J. Proteom. Res. 2012, 11:554-563.
90. Chaika N.V., Gebregiworgis T., Lewallen M.E., et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc. Natl. Acad. Sci. USA 2012, 109:13787-13792.
91. Guillaumond F., Leca J., Olivares O., et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc. Natl. Acad. Sci. USA 2013, 110:3919-3924.